Pacific Edge Ltd (NZSE:PEB) Share Price

Company Profile

Business description
Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.
Contact
87 St David Street
P.O. Box 56
DunedinSTL9016
NZL
T: +64 35776733
https://www.pacificedgedx.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2026
Employees
34

Recommended

This company dominates its industry and could be flirting with regulatory intervention.

Roy Van Keulen | 07 August 2025

Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.

Mark Giarelli | 07 August 2025

Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?

Joseph Taylor | 06 August 2025

Index	Last price	Change	% Change
All Ordinaries	9,088.70	22.40	-0.25%
CAC 40	7,635.03	13.99	0.18%
DAX 40	23,924.36	78.29	0.33%
Dow JONES (US)	44,193.12	81.38	0.18%
FTSE 100	9,164.31	21.58	0.24%
HKSE	25,018.97	108.34	0.43%
NASDAQ	21,169.42	252.87	1.21%
Nikkei 225	41,081.22	286.36	0.70%
NZX 50 Index	12,922.20	42.04	0.33%
S&P 500	6,345.06	45.87	0.73%
S&P/ASX 200	8,819.20	24.50	-0.28%
SSE Composite Index	3,638.40	4.40	0.12%